Stimulation of reactive astrogliosis in vivo by extracellular adenosine diphosphate or an adenosine A2 receptor agonist.
Adenosine and its nucleotides adenosine triphosphate (ATP) and adenosine diphosphate (ADP) stimulate the proliferation of brain astrocytes in vitro and augment the effects of other growth factors. Following brain injury, hypoxia, or around solid tumors with necrotic centers, such as glioblastoma multiformes, high concentrations of adenine nucleotides and adenosine are released into the extracellular space; extracellular adenosine concentrations can rise 30-100-fold to a concentration in excess of 100 microM. Increased concentrations of extracellular adenosine and adenine nucleotides may contribute to reactive astrocytic proliferation following brain injury. To test this hypothesis, adenosine, an adenosine analog 5'-(N-cyclopropyl)-carboxamidoadenosine (CPCA), or ADP was micro-injected into rat cortex. The number of glial fibrillary acidic protein-immunopositive cells was compared between the treated and contralateral saline-injected hemispheres. Within 48 hr, astrocyte density around the CPCA (100 microM) infusion site was almost double that around the control saline infusion site. In hemispheres into which CPCA was infused, there was an increase in astrocytes in the subpial region along fiber tracts and around blood vessels, characteristic of Scherer's secondary structures found in association with malignant astrocytic brain tumors. The increased astrogliosis elicited by CPCA was abolished by coinfusion of the adenosine A2 receptor antagonist 1,3-dipropyl-7-methylxanthine (DPMX). While microinjection of adenosine (1 mM) failed to stimulate astrogliosis, microinjection of ADP (500 microM) also resulted in a significant reactive astrogliosis and accumulation of astrocytes similar to Scherer's secondary structures.(ABSTRACT TRUNCATED AT 250 WORDS)
Hindley
S
S
Department of Biomedical Sciences, McMaster University Health Science Center, Hamilton, Ontario, Canada.
Herman
M A
MA
Rathbone
M P
MP
D000241:Adenosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000244:Adenosine Diphosphate / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D001253:Astrocytes / Q000187:drug effects / Q000502:physiology*; D005455:Fluorescent Antibody Technique; D005904:Glial Fibrillary Acidic Protein / Q000096:biosynthesis; D007150:Immunohistochemistry; D008297:Male; D008845:Microinjections; D058906:Purinergic P1 Receptor Agonists; D051381:Rats; D017208:Rats, Wistar; D014970:Xanthines / Q000494:pharmacology
D005904:Glial Fibrillary Acidic Protein; D058906:Purinergic P1 Receptor Agonists; D014970:Xanthines; C059953:1,3-dipropyl-7-methylxanthine; C024311:N-cyclopropyl adenosine-5'-carboxamide; D000244:Adenosine Diphosphate; D000241:Adenosine